Engineered immune cells take on liver cancer in new trial

NCT ID NCT06590246

Recruiting now Disease control Sponsor: Shanghai AbelZeta Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called C-CAR031 for adults with advanced or recurrent liver cancer that has not responded to at least two prior therapies. C-CAR031 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 121 participants to check safety and whether the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: C-CAR031 (armored GPC3-targeted CAR T-cells)
What this could lead to: If successful, this could offer a new treatment option for people with advanced liver cancer who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 121 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hanzhou, Zhejiang, 310003, China
ZhongShan Hospital Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.